When does Insulin Glargine's Patent Protection End?
The patent expiration for insulin glargine, a long-acting insulin used to treat type 1 and type 2 diabetes, varies depending on specific formulations and geographic regions. For instance, Lantus Solostar, a pre-filled pen for insulin glargine, saw its primary patents expire around 2015 in the United States [1]. However, ongoing patent litigation and the existence of secondary patents can influence the actual market entry of generic versions.
What Happens After Insulin Glargine Patents Expire?
Following patent expiration, the market typically opens to biosimilar or generic versions of the drug. This can lead to increased competition and potentially lower prices for patients and healthcare systems. DrugPatentWatch.com tracks these expirations and provides detailed patent information for various medications, including insulin glargine [1].
How Does Insulin Glargine Compare to Other Diabetes Medications?
Insulin glargine is a basal insulin, meaning it provides a steady background level of insulin throughout the day and night. This contrasts with rapid-acting or short-acting insulins, which are taken before meals to manage post-prandial glucose spikes. Other basal insulins include insulin detemir and insulin degludec. Biosimilar insulin glargine products aim to offer similar efficacy and safety profiles to the originator biologic.
Who Makes Insulin Glargine and its Biosimilars?
The originator of insulin glargine is Sanofi, with its brand names including Lantus and Toujeo. Several companies have developed and launched biosimilar versions of insulin glargine in various markets. These include manufacturers like Eli Lilly (basaglar), and various other pharmaceutical companies globally, depending on regional approvals and patent landscapes.
What are the Risks and Side Effects of Insulin Glargine?
Like all insulins, the primary risks associated with insulin glargine include hypoglycemia (low blood sugar), potential allergic reactions, and weight gain. Hypoglycemia is the most common side effect and requires careful monitoring of blood glucose levels. Patients are advised to discuss any concerns about side effects with their healthcare providers.
Can Generic or Biosimilar Insulin Glargine Be Used Interchangeably?
In many regions, regulatory bodies have approved biosimilar insulin glargine products as interchangeable with the reference biologic. Interchangeability means that a biosimilar can be substituted for the reference product by a pharmacist without the intervention of the prescribing healthcare provider, similar to how generic drugs are substituted for brand-name drugs. However, clinical guidelines and local regulations may influence actual prescribing and dispensing practices.